Perficient: Drug Development

FEBRUARY 15, 2024

Issues and Findings Management: Document issues and gaps identified during risk assessments and control testing, crucial for compliance. Compliance Requirements Institutions falling under the purview of the NYSDFS Part 500 amendments encompass a diverse spectrum, all mandated to adhere to these regulations.

Compliance 52

Compliance Regulations Licensing Licensing 52

Perficient: Drug Development

JULY 17, 2024

This process is well documented. I read through this documentation multiple times and did not really understand the process until I needed to implement it for myself. In order to identify a guest, we must send an “IDENTITY” event. If you have been confused by identity in CDP, read on! CDP allows the same behavior digitally.

Licensing 52

Licensing Licensing International 52

Molecule Blog

AUGUST 6, 2021

An Open Bazaar for Drug Development: Molecule Protocol The complexity of biopharma IP deals When examining the transactional market for biopharma IP, one aspect becomes immediately obvious: IP is not sold in a simple purchase agreement like houses, cars or other physical objects.

Licensing 52

Licensing Licensing Marketing Research 52

Molecule Blog

JANUARY 9, 2023

IP-NFTs upgrade our legacy intellectual system by unifying IP (patents, legal), underlying data (through decentralized storage and access control), and economics (royalties, license fees, sales) into one programmable, transactable, digital unit. ‍ How will IP-NFTs enable drug development in the future?

Research 52

Research Licensing Licensing Science 52

Conversations in Drug Development Trends

AUGUST 9, 2024

Managing this complexity highlights the importance of global communication plans and constant communication with global regulators and keeping all required documentation up to date. An import license is necessary for any intellectual property or equipment used during the trial.

Trials 80

Trials Clinical Trials Regulations FDA 80

Perficient: Drug Development

JANUARY 18, 2024

To convert and compress the Sitecore license to base 64 string, run the script present in “ConvertTo-CompressedBase64String” method present in the upgrade guide. Review the readme and KCD Documentation file. Execute the scripts as mentioned in the documentation. DATABASE_UPGRADE_TO_VERSION=10.3.1

Licensing 52

Licensing Licensing 52

Agency IQ

MAY 10, 2024

What life sciences companies need to know about NIST’s new AI guidance The National Institute of Standards and Technology (NIST) last week released four new documents on artificial intelligence, mostly focusing on generative AI (GAI). development, deployment, real-world monitoring). Number three: Dangerous or violent recommendations.

Science 40

Science FDA Production Regulations 40

Agency IQ

AUGUST 2, 2024

An earlier iteration of that report detailed how the agency wanted to change some of its practices surrounding the publication of guidance documents. However, the draft document was somewhat FDA-focused, and industry asked the agency to incorporate other ideas into the final version. This is what OIRA is currently reviewing.

FDA 40

FDA Science Regulations Biosimilars 40

Drug Discovery World

MARCH 29, 2023

According to the Wellcome Trust 5 , it can take between 10 and 15 years and over $1billion to develop a new antibiotic, so systems such as this aim to provide incentive to drug developers.

Clinical Trials 130

Clinical Trials Biosimilars Pharma Companies Production 130

Perficient: Drug Development

JANUARY 19, 2024

This distribution utilizes licensed API keys, streamlining the process for customers to conveniently retrieve and access these containers in their local registries or incorporate them seamlessly into their CI/CD pipelines.

Compliance 118

Compliance Marketing Licensing Licensing 118

Drug Discovery World

OCTOBER 12, 2022

Beyond that, there are other operational considerations associated with deploying sensors in a global clinical trial, including documentation to support Clinical Trial Applications in various jurisdictions, training of sites and patients, and ongoing support to achieve high compliance and high data yield. About the author .

Clinical Trials 130

Clinical Trials Trials Disease Clinical Research 130

Perficient: Drug Development

MARCH 29, 2024

Storybook promotes the Component-Driven Development (CDD) approach, where every part of the user interface is a component. Each of them is developed, tested, and documented separately from the others, which simplifies the process of developing and maintaining the application as a whole.

Compliance 52

Compliance Licensing Licensing Production 52

Perficient: Drug Development

NOVEMBER 7, 2023

Here we will outline several distinctions between two prominent tools: Acunetix and Burp Suite: Aspect Acunetix Burp Suite Scanner Vendor Acunetix by Invicti Security Burp Suite by PortSwigger User Interface User-friendly, guided scans Comprehensive, flexible interface Scanning Depth Deep scanning capabilities Deep and extensive scanning Automated (..)

Licensing 52

Licensing Licensing 52

Agency IQ

MAY 3, 2024

FDA’s Diversity Action Plan guidance: The FDA’s hotly-anticipated revised draft guidance document is currently under review at the White House’s Office of Information and Regulatory Affairs (OIRA), and we anticipate that it will be published over the next two months.

FDA 40

FDA Science Regulations Clinical Trials 40

Agency IQ

AUGUST 16, 2024

By Amanda Conti | Aug 13, 2024 10:00 PM CDT Regulatory context: Psychedelic regulation and drug development A growing body of evidence suggests that psychedelics may provide clinical benefit for certain purposes, especially mental health conditions.

FDA 40

FDA Trials Regulations Therapies 40

Agency IQ

MARCH 1, 2024

FDA March 13 BLA Regulation FDA’s Biologics License Applications and Master Files rule becomes effective FDA March 25 Quality Management Maturity Deadline to participate in the Quality Management Maturity Prototype Assessment Protocol Evaluation Program. Must also provide list of recommended documentation for AI contracts.

FDA 40

FDA Science Clinical Trials Regulations 40

Agency IQ

JULY 12, 2024

FDA gives companies leeway to go after misinformation, but not free reign In a new revised draft guidance document, the FDA says it will allow life sciences companies to address misinformation about their products that is posted online. sponsors, developers and manufacturers] to disseminate information about drugs and devices.”

FDA 40

FDA Regulations Production Science 40

Perficient: Drug Development

JUNE 15, 2023

license applies to Playwright, which is most widely used with NodeJS and Javascript/Typescript. Playwright Test was developed especially to meet the requirements of end-to-end testing. Despite the excellent documentation of Playwright, little support from the community may be anticipated. The Apache 2.0 There is no IE11 support.

Marketing 52

Marketing Licensing Licensing Engineering 52

Perficient: Drug Development

SEPTEMBER 25, 2023

Note : To be able to use the checkpoint functionality, we need to have an enterprise edition license. In this comprehensive blog, we’ll embark on the journey of mastering Katalon Studio: Checkpoints and Visual Checkpoints, with step-by-step instructions on how to leverage these features for effective testing.

Licensing 52

Licensing Licensing 52

Agency IQ

JUNE 2, 2023

We’ve also included documents that are actively under White House review, which often takes several weeks (or months). Note: If a link no longer works, it is likely because OIRA has since cleared the document.) This is what OIRA is currently reviewing. Note: If a link no longer works, it is likely because OIRA has since deleted it.)

FDA 40

FDA Science Regulations Production 40

LifeSciVC

JANUARY 25, 2024

This rough patch has been well documented in this space and particularly tough. And so the effort required to successfully commercialize a drug in the U.S. I have had the good fortune to experience each stage of these discovery and drug development challenges in my career. and globally is also a huge lift for a company.

Science 71

Science Clinical Trials Trials Medical Schools 71

FDA Law Blog: Biosimilars

MARCH 13, 2024

The PTE application states “[u]nder the terms of the AMENDED AND RESTATED DEVELOPMENT AND COMMERCIALIZATION LICENSE AGREEMENT between Pfizer Inc. exclusively licensed U.S. However, an exclusive license is not an authorization to rely on the activities of the marketing applicant for a PTE application. and OPKO Ireland Ltd.

FDA 59

FDA FDA Approval Marketing Production 59

The Pharma Data

OCTOBER 26, 2020

Fast Track designation allows for early and frequent communication with the FDA throughout the entire drug development and review process. It may also allow for priority or rolling review of a company’s Biologics License Application (BLA).

FDA 40

FDA Disease Treatment Therapies 40

Agency IQ

FEBRUARY 2, 2024

The documents describe all the guidance documents that are under development and that may be published in a given year. Note: If a link no longer works, it is likely because OIRA has since cleared the document.) This is what OIRA is currently reviewing. Report will contain information specified in the commitment letter.

FDA 40

FDA Science Clinical Trials Regulations 40

Agency IQ

FEBRUARY 15, 2024

166 guidance documents the FDA is actively working on in 2024 (and beyond) The FDA is set to be very, very busy in 2024. We’ve identified a total of 166 guidance documents that are under active development, and have the key details for you below. Some of those documents may also take years to be completed.

FDA 40

FDA Science Biosimilars Production 40

The Pharma Data

OCTOBER 27, 2020

The FDA grants Orphan Drug designation to drugs and biologics intended for the treatment, diagnosis or prevention of rare diseases or conditions affecting fewer than 200,000 people in the United States.

Disease 40

Disease FDA Treatment Clinical Trials 40

Agency IQ

MAY 31, 2024

Unpacking FDA’s long-awaited platform technology designation program and guidance Months overdue, the FDA’s Platform Technologies Designation guidance document has just been published by the agency. AgencyIQ breaks down what the designation means for sponsors and its limits for product sponsors.

Science 40

Science FDA Production Licensing 40

The Pharma Data

DECEMBER 17, 2020

These follow-on data provided the first definitive prospective evidence demonstrating anti-viral activity for a treatment regimen now available for COVID-19, and also further documented the ability of this treatment to decrease the need for further medical attention,” said George D. Yancopoulos , M.D.,

Hospitals 52

Hospitals Production Clinical Trials Virus 52

Agency IQ

SEPTEMBER 1, 2023

FDA finalizes guidance on oversight of RWE studies, making several significant changes The FDA today finalized a much-anticipated guidance document on how sponsors of drugs and biologics can oversee and make use of their non-interventional studies involving real-world data and evidence.

FDA 40

FDA Science Regulations Production 40

Agency IQ

SEPTEMBER 29, 2023

That will have meant that FDA flagrantly missed its deadline to issue a guidance document related to medical countermeasure submissions and the use of Drug Master Files for platform technologies, which was due June 24, 2022. FDA is also due to revise 24 other guidance documents at that time.

FDA 40

FDA Science Regulations Production 40

Agency IQ

JUNE 29, 2023

We’ve also included documents that are actively under White House review – a process which often takes several weeks (or months) to conclude. Note: If a link no longer works, it is likely because OIRA has since cleared the document.) This is what OIRA is currently reviewing.

FDA 40

FDA Science Regulations Production 40

Agency IQ

OCTOBER 27, 2023

While the FDA previously published a similar version of this document, Congress gave FDA new authority to require these plans. Expect nearly every company to be closely reading this document when it’s eventually published. FDA is also due to revise 24 other guidance documents at that time. AgencyIQ November 18 Shutdown (?)

FDA 40

FDA Science Regulations Production 40

Agency IQ

FEBRUARY 12, 2024

A closer look at CDER’s new 2024 guidance agenda The FDA’s Center for Drug Evaluation and Research, its drug review division, this week quietly updated its 2024 Guidance Agenda, a list of all draft guidance documents the agency is working on this calendar year. This list is known as the FDA’s “guidance agenda.”

Biosimilars 40

Biosimilars Science Clinical Pharmacology FDA 40

Agency IQ

DECEMBER 1, 2023

While the FDA previously published a similar version of this document, Congress gave FDA new authority to require these plans. Expect nearly every company to be closely reading this document when it’s eventually published. Note: If a link no longer works, it is likely because OIRA has since cleared the document.)

FDA 40

FDA Science Regulations Production 40

The Pharma Data

SEPTEMBER 8, 2020

The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

The Pharma Data

SEPTEMBER 8, 2020

The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. available at. sec.gov. , for a discussion of these and other risks and uncertainties.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

Perficient: Drug Development

JANUARY 25, 2024

The documentation is not yet available at this moment, but … everything is so absolutely intuitive, that you hardly need one, don’t you? Licensing Since Forms are bundled into XM Cloud they’re included with every XM Cloud subscription. app, as part of pull request merged into this release. What is missing?

Licensing 75

Licensing Licensing Production Marketing 75